Abstract
Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.
| Original language | English |
|---|---|
| Pages (from-to) | 787-804 |
| Number of pages | 18 |
| Journal | Pharmacotherapy |
| Volume | 20 |
| Issue number | 7 I |
| State | Published - 2000 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Advances in the treatment of congestive heart failure : New approaches for an old disease. / Skrabal, Maryann Z.; Stading, Julie A.; Behmer-Miller, Kathryn A.; Hilleman, Daniel E.
In: Pharmacotherapy, Vol. 20, No. 7 I, 2000, p. 787-804.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Advances in the treatment of congestive heart failure
T2 - New approaches for an old disease
AU - Skrabal, Maryann Z.
AU - Stading, Julie A.
AU - Behmer-Miller, Kathryn A.
AU - Hilleman, Daniel E.
PY - 2000
Y1 - 2000
N2 - Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.
AB - Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.
UR - http://www.scopus.com/inward/record.url?scp=0033946172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033946172&partnerID=8YFLogxK
M3 - Review article
VL - 20
SP - 787
EP - 804
JO - Pharmacotherapy
JF - Pharmacotherapy
SN - 0277-0008
IS - 7 I
ER -